Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer First regulatory designation for M7824 following recent presentation of first clinical data in BTC BTC is a group of rare, aggressive g... Biopharmaceuticals, Oncology, FDA Merck KGaA, Immunotherapy, M7824, Biliary Tract Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news